Intellia Therapeutics
NTLA
10.00
+0.48
+5.04%
Intellia Therapeutics
US · NTLA
#2899 by market cap
Listed 2016
10.00
+0.48
+5.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Hold
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
3 6
■ Upgrades■ Downgrades
- 3 upgrades vs 6 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Buy to Sell on 2026-10-06.
Analyst consensus 11 analysts
Hold
Avg price target 19.20 +92.0%
Price target rangecurrent 10.00
Low8.00
Avg19.20
High49.00
Buy 36%
Hold 45%
Sell 18%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | BofA Securities | -- | Hold | 16.00 |
| 2026-11-13 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-11-09 | CCORF | -- | Buy | 49.00 |
| 2026-11-09 | J.P. Morgan | -- | Sell | 9.00 |
| 2026-11-06 | JonesTrading | -- | Buy | 27.00 |
| 2026-11-06 | BofA Securities | -- | Hold | 16.00 |
| 2026-11-06 | Wedbush | -- | Hold | 13.00 |
| 2026-11-06 | Morgan Stanley | -- | Hold | 15.00 |
| 2026-11-06 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-11-05 | RBC Capital | -- | Hold | 15.00 |
| 2026-10-15 | Wells Fargo | -- | Hold | 15.00 |
| 2026-10-07 | Barclays | -- | Sell | 8.00 |
| 2026-10-06 | Barclays | -- | Sell | 8.00 |
| 2026-09-09 | Wedbush | -- | Hold | 13.00 |
| 2026-09-09 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-09-04 | TD Cowen | -- | Buy | -- |
| 2026-08-14 | JonesTrading | -- | Buy | 29.00 |
| 2026-08-10 | Morgan Stanley | -- | Hold | 15.00 |
| 2026-08-07 | BofA Securities | -- | Hold | 17.00 |
| 2026-08-07 | Evercore | -- | Buy | 24.00 |
| 2026-08-07 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-08-06 | CCORF | -- | Buy | 49.00 |
| 2026-08-06 | William Blair | -- | Buy | -- |
| 2026-08-06 | Evercore | -- | Buy | 24.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-06 | Barclays | Buy → Sell | 8.00 |
| 2026-08-06 | Evercore | Hold → Buy | 24.00 |
| 2026-07-15 | Wolfe Research | Hold → Sell | 9.00 |
| 2026-04-28 | Evercore | Buy → Hold | 16.00 |
| 2026-03-04 | JonesTrading | Hold → Buy | 29.00 |
| 2026-03-02 | William Blair | Hold → Buy | -- |
| 2025-11-11 | JonesTrading | Buy → Hold | -- |
| 2025-11-07 | J.P. Morgan | Hold → Sell | 5.00 |
| 2025-10-31 | BofA Securities | Buy → Hold | 14.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | -- | ±11.82% | +2.46% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±17.42% | +6.41% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±20.15% | +0.79% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±21.04% | +13.58% (in line) |
| 2024/Q4 | 2025-02-27 | -- | ±23.48% | +0.56% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±13.59% | -0.37% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±19.43% | +5.02% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±15.08% | +8.09% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±19.29% | +1.12% (in line) |
| 2023/Q3 | 2023-11-09 | -- | ±13.81% | -12.27% (in line) |
| 2023/Q2 | 2023-08-03 | -- | ±15.20% | -1.56% (in line) |
| 2023/Q1 | 2023-05-04 | -- | ±15.25% | +13.14% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.
Intellia Therapeutics discussion 0 comments